Head & Neck Cancers | Specialty

The OncLive Head and Neck Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with head and neck cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research within head and neck cancer.

Acupuncture Shows Potential for Xerostomia

March 13th 2012

Acupuncture may help prevent xerostomia in patients with nasopharyngeal carcinoma undergoing radiotherapy and may also reduce symptom severity.

HPV Plays Growing Role in Evaluating Therapies

February 16th 2012

Researchers are dissecting new studies regarding targeted therapies as well as combined therapeutic approaches for HPV in the progression of head and neck cancers.

Addition of Bevacizumab May Help in Nasopharyngeal Cancer

February 7th 2012

Researchers are reporting favorable early results with the addition of bevacizumab to conventional chemoradiation in patients with advanced nasopharyngeal cancer.

Dr. Cohen on mTOR Inhibition in Head and Neck Cancer

February 3rd 2012

Dr. Ezra Cohen, from University of Chicago, on mTOR Inhibition in Head and Neck Cancer

HPV and the Rise of Head and Neck Cancers

February 3rd 2012

Human papillomavirus is perhaps best known as the main cause of cervical cancer, but if recent trends continue, by 2020 HPV will cause more cases of oropharyngeal cancer each year than cervical cancer.

Mouth Care Systems Alleviate Xerostomia After Radiotherapy

January 31st 2012

Radiotherapy often results in the loss of some salivary gland function, causing hyposalivation and xerostomia.

Oral HPV Infections More Prevalent in Men

January 26th 2012

Approximately 7% of Americans carry the human papillomavirus (HPV) in their oral cavities, and men are 3 times more likely to carry the virus than women.

Minimally Invasive Surgeries Retain Place in Treatment Plan

January 12th 2012

In an era when advances in chemoradiation and targeted therapies have revolutionized treatment in head and neck oncology patients, it's possible that treating physicians might not know where surgery fits into the regimen.

Dr. Burtness on 2 Types of Head and Neck Cancer

January 6th 2012

Dr. Barbara Burtness, from Fox Chase Cancer Center, on the 2 Types of Head and Neck Cancer

Chemoradiotherapy Shows Promise in Nonmelanoma Skin Cancer of the Head and Neck

January 4th 2012

Chemotherapy given at the same time as radiotherapy may be a feasible treatment for high-risk nonmelanoma skin cancer (NMSC) of the head and neck.

Exelixis Finds Great Promise in Cabozantinib

December 28th 2011

The investigational compound cabozantinib (formerly known as XL184) has generated much excitement in recent years for its ability to target multiple pathways involved in the development of cancer.

Hair Professionals Often Check Customers for Worrisome Skin Lesions

December 20th 2011

Some cosmetologists and barbers inspect their customers' scalps, necks, and faces for the presence of skin lesions that they think may be cancerous.

HPV Vaccine Recommendation for Boys Viewed as Necessary

December 19th 2011

As the incidence of head and neck cancers linked to the HPV continues to rise, a federal advisory panel has recommended that all 11- and 12-year-old boys be vaccinated against the virus.

Dr. Vokes on Cetuximab for Head and Neck Cancer

December 6th 2011

Dr. Everett Vokes from University of Chicago Medical Center on Cetuximab for Head and Neck Cancer

Dr. Sherman Discusses the Vandetanib Trial

December 5th 2011

Dr. Eric Sherman from Memorial Sloan-Kettering Cancer Center Discusses the Vandetanib Trial

Dr. Mehra Discusses DNA Repair Enzymes

December 5th 2011

Dr. Ranee Mehra from Fox Chase Cancer Center Discusses DNA Repair Enzymes

Focusing on EGFR Resistance

December 1st 2011

Ezra E. W. Cohen, MD, has focused on the role of EGFR inhibitors in much of his research into head and neck cancers.

Dr. Cohen Discusses Head and Neck Cancer Pathways

November 29th 2011

Dr. Ezra Cohen from the University of Chicago Discusses Head and Neck Cancer Pathways

Turmeric Ingredient Inhibits Kinase in Cancer Pathway

November 21st 2011

If IKK kinase, a group of inhibitory proteins, activity is not regulated properly, tumors in the body have the ability to migrate and proliferate.

Making Oncology His Path: An Interview With Ezra E.W. Cohen, MD

November 15th 2011

Ezra E. W. Cohen, MD, is a physician and translational researcher at the University of Chicago Medical Center, that focuses on epidermal growth factor receptor (EGFR) inhibitors.